Vo Nam Xuan, Le Ngan Nguyen Hoang, Chu Trinh Dang Phuong, Pham Huong Lai, Dinh Khang Xuan An, Che Uyen Thi Thuc, Ngo Thanh Thi Thanh, Bui Tien Thuy
Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
Faculty of Pharmacy, Le Van Thinh Hospital, Ho Chi Minh City 700000, Vietnam.
Pharmacy (Basel). 2023 Jul 14;11(4):117. doi: 10.3390/pharmacy11040117.
Knee osteoarthritis is the most popular type of osteoarthritis that causes extreme pain in the elderly. Currently, there is no cure for osteoarthritis. To lessen clinical symptoms, glucosamine was suggested. The primary goal of our systematic review study is to evaluate the effectiveness and safety of glucosamine based on recent studies. Electronic databases such as PubMed, Scopus, and Cochrane were used to assess the randomized controlled trial (RCT). From the beginning through March 2023, the papers were checked, and if they fulfilled the inclusion criteria, they were then examined. The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) and Visual Analog Scale (VAS) scales were considered the main outcome measures. A total of 15 studies were selected. Global pain was significantly decreased in comparison to placebo, as measured by the VAS index, with an overall effect size of standardized mean difference (SMD) of -7.41 ([95% CI] 14.31, 0.51). The WOMAC scale confirmed that pain, stiffness, and physical function had improved, however the effects were insufficient. A statistical update also revealed that there were no reports of serious medication interactions or significant adverse events. To summarize, glucosamine is more effective than a placebo at reducing pain in knee osteoarthritis patients. In long-term treatment, oral glucosamine sulfate 1500 mg/day is believed to be well tolerated.
膝关节骨关节炎是最常见的骨关节炎类型,会给老年人带来剧痛。目前,骨关节炎无法治愈。为减轻临床症状,有人提出使用氨基葡萄糖。我们这项系统评价研究的主要目的是根据近期研究评估氨基葡萄糖的有效性和安全性。使用诸如PubMed、Scopus和Cochrane等电子数据库来评估随机对照试验(RCT)。从开始到2023年3月,对论文进行筛选,若符合纳入标准,则进一步审查。以西安大略和麦克马斯特大学骨关节炎指数(WOMAC)和视觉模拟量表(VAS)作为主要结局指标。共筛选出15项研究。通过VAS指数测量发现,与安慰剂相比,总体疼痛显著减轻,标准化平均差(SMD)的总体效应量为-7.41([95%置信区间]14.31,0.51)。WOMAC量表证实疼痛、僵硬和身体功能有所改善,但效果并不显著。一项统计更新还显示,没有严重药物相互作用或重大不良事件的报告。总之,氨基葡萄糖在减轻膝关节骨关节炎患者疼痛方面比安慰剂更有效。在长期治疗中,每天口服1500毫克硫酸氨基葡萄糖被认为耐受性良好。